Cadrenal Therapeutics Inc (CVKD)

[oldstocks]

$CVKD FORM 8-K CURRENT REPORT

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001937993/000101376223005859/ea187126-8k_cadrenal.htm

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 20, 2023

Cadrenal Therapeutics, Inc.
822 A1A North, Suite 306
Ponte Vedra, Florida 32082

[phone]
Ticker CVKD

On October 20, 2023, Cadrenal Therapeutics, Inc. (the “Company”), held its 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) where the Company’s stockholders voted on the following two (2) proposals and cast their votes as described below. These matters are described in detail in the Company’s definitive proxy statement as filed with the Securities and Exchange Commission on August 28, 2023 (the “Proxy Statement”).

As of August 25, 2023, the record date of the 2023 Annual Meeting, there were 13,022,754 issued and outstanding shares of common stock entitled to vote at the 2023 Annual Meeting. Present in person or by proxy at the 2023 Annual Meeting were more than thirty-four percent (34%) of the issued and outstanding capital stock entitled to vote at the 2023 Annual Meeting, which constituted a quorum.

The final voting results from the 2023 Annual Meeting for Proposals No. 1 and 2, as described in the Proxy Statement, is set forth below.

Proposal 1. Election of Directors.

The following two (2) individuals were elected as Class I directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified with the following votes:
Quang Pham
Glynn Wilson

Proposal 2. Ratification of the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023.

The stockholders ratified and approved the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 based on the votes listed below:
Dated: October 23, 2023 CADRENAL THERAPEUTICS, INC. Quang Pham Chairman and Chief Executive Officer